Skip to main content
Equibles

ZYBT · Zhengye Biotechnology Holding Ltd

Track ZYBT — free

Use ZYBT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZYBT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.50 +0.04 (+2.74%)
Rebalance outlook locked
Market Cap
$69.90M
Shares
47.39M
Volume · Oct 22 82.17K Avg daily vol (3M) 2.42M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.46 Open$1.43 Day$1.43–1.53 52W close$0.65–8.01 Avg vol 30d1.2M Short int115K · 0.2% float · 5.6d Short vol50% DataJan 2025–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-37.6%
Year over year
Operating margin
-60.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.7%
Year over year · more shares
Price change (1Y)
-41.8%
Trailing year
Short interest
0.2%
Latest settlement · 5.6 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 16.7 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +27%
above
Price vs 50-day avg −3%
below
RSI (14) 52
neutral
MACD trend Positive
52-week position 11%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +7%
trailing
6-month return +59%
trailing
YTD return +27%
this year
Relative strength +51%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.24% of float · ▼ -16.1% MoM · 5.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
8 holders — mid 1-yr range
Squeeze score 43
elevated · 0–100
Fundamentals
Weak
Revenue growth −35%
Y/Y
Gross margin 21%
contracting
EPS growth −64%
Y/Y
Free cash flow $1.8M
Balance sheet $3.5M
net debt
Quant / Vol
risk profile
Very High
Volatility 1064%
annualized · 1-yr
Max drawdown −86%
past year
ATR 15.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+27% Bullish
Price vs 50-day avg
−3% Neutral
RSI (14)
52 Neutral
MACD trend
Positive Bullish
52-week position
11% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.24% of float · ▼ -16.1% MoM · 5.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
8 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 11% Range high $8
vs 200-day avg +27% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ZYBT
Zhengye Biotechnology Holding Ltd
this stock
$69.90M +27.0% -34.8% — 0.2%
TAK
Takeda Pharmaceutical Co Ltd
 $64.50B +27.8% — — 0.1%
GALDY
Galderma Group AG
 $49.23B +1.9% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $46.52B +30.2% +4.3% 65.4 2.6%
HLN
Haleon plc
 $44.06B -0.9% — — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
8
% held
0.2%
Net QoQ
-20.8K sh
Top holder
XTX Topco Ltd
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
115.1K
Days to cover
5.6d
Change
-22.1K sh
View
Short Volume
Short vol %
50%
As of
Oct 21, 2026
Short Total
View
Fails to Deliver
FTD shares
532
Value
$729
As of
Sep 18, 2026
View
Off-Exchange
Off-exchange %
48.4%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
CNY 116.4M
Net income (FY)
CNY -69.8M
EPS diluted
CNY 0.25
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 6, 2026
This year
7
View
Proposed Sales
Value
$1.8M
Shares
685.0K
Filed
Oct 22, 2025
View
Earnings & Events
Webcasts
Last webcast
May 22, 2026
View

Performance

5D 20D 120D MTD YTD
ZYBT -4.6% +6.6% +58.7% +21.7% +27.0%
SPY +0.5% +0.7% +7.6% +1.4% +13.4%
vs SPY -5.0% +5.9% +51.1% +20.3% +13.6%
Key facts CIK 1975641 CUSIP G989MS101 Visit website Investor relations